Reduction in the incidence of MACE (hazard ratio of 0.88). A 12% reduction in a patient taking dulaglutide as compared to the placebo. A 16% decrease in non-fatal stroke. 12% reduction in CVS mortality.  Slower increase in cardiac biomarkers compared to placebo, mainly NT-pro-BNP and GDF-15. The gene discussed is GDF15; the disease is stroke disorder.